Tridek-One logo

Tridek-One

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

12 employees · est. 2018 · Paris, France

VS
XBiotech USA, Inc. logo

XBiotech USA, Inc.

Next Generation Antibody Therapy

97 employees · est. 2005 · Austin, United States

XBiotech USA, Inc. is the older company (2018 vs 2005); XBiotech USA, Inc. is the larger of the two.

Side-by-Side Comparison

Tridek-One XBiotech USA, Inc.
Founded
2018 2005 older
Headquarters
Paris, France Austin, United States
Employees
12 97 larger
Industry
Biotechnology, Health Care, Life Sciences Biotechnology, Health Care
Funding Stage
Series Unknown Not tracked yet
Total Funding
$19.00M Not tracked yet
Funding Rounds
2 Not tracked yet
Services
Development of first-in-class CD31 checkpoint agonists for the treatment of autoimmune and inflammatory diseases. Not tracked yet
Target Customers
Patients with autoimmune and inflammatory diseases, healthcare providers, pharmaceutical companies, and biotech research institutions. Not tracked yet
Taxonomy
Immunomodulation, Therapeutic Antibodies, Autoimmune Diseases, Inflammatory Disorders, Biopharmaceuticals, Immunotherapy, Drug Development, Immune Checkpoint Modulation, Monoclonal Antibodies, Immunological Research, Therapeutic Innovation, Immune System Modulation, Clinical Development, Autoimmune Therapy Biopharmaceuticals, Antibody Therapy, True Human™ Antibodies, Oncology, Inflammatory Conditions, Infectious Diseases, Clinical Trials, Drug Development, Therapeutic Antibodies, Immunotherapy, Precision Medicine, Disease Treatment, Medical Research, Immunology
Website
tridekone.com xbiotech.com
Tridek-One logo

About Tridek-One

Tridek-One is a French biotechnology startup founded in 2018, specializing in the development of first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company's focus on anti-CD31 ago...

XBiotech USA, Inc. logo

About XBiotech USA, Inc.

XBiotech USA, Inc. is a pioneering global biosciences company specializing in the discovery, development, and commercialization of therapeutic antibodies using its True Human™ proprietary technology. Unlike traditional antibody therapies, XBiotech’s True Human™ antibodies are derived from individual...

We will tell you when either one moves

BounceWatch watches Tridek-One and XBiotech USA, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Tridek-One and XBiotech USA, Inc. — by email.

Frequently Asked Questions

Tridek-One — We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases. XBiotech USA, Inc. — Next Generation Antibody Therapy. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Tridek-One has raised $19.00M while XBiotech USA, Inc. has raised undisclosed funding.
Tridek-One and XBiotech USA, Inc. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Tridek-One with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Tridek-One on 7 Jun 2025, and XBiotech USA, Inc. on 16 Nov 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy